625 related articles for article (PubMed ID: 23949829)
1. Atypical aging in Down syndrome.
Zigman WB
Dev Disabil Res Rev; 2013; 18(1):51-67. PubMed ID: 23949829
[TBL] [Abstract][Full Text] [Related]
2. Aging and intellectual disability: insights from mouse models of Down syndrome.
Ruparelia A; Pearn ML; Mobley WC
Dev Disabil Res Rev; 2013; 18(1):43-50. PubMed ID: 23949828
[TBL] [Abstract][Full Text] [Related]
3. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease in Down syndrome: neurobiology and risk.
Zigman WB; Lott IT
Ment Retard Dev Disabil Res Rev; 2007; 13(3):237-46. PubMed ID: 17910085
[TBL] [Abstract][Full Text] [Related]
5. Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.
Wilcock DM; Hurban J; Helman AM; Sudduth TL; McCarty KL; Beckett TL; Ferrell JC; Murphy MP; Abner EL; Schmitt FA; Head E
Neurobiol Aging; 2015 Sep; 36(9):2468-74. PubMed ID: 26103884
[TBL] [Abstract][Full Text] [Related]
6. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
[TBL] [Abstract][Full Text] [Related]
7. Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome.
Hartley SL; Fleming V; Schworer EK; Peven J; Handen BL; Krinsky-McHale S; Hom C; Lee L; Tudorascu DL; Laymon C; Minhas D; Luo W; Cohen A; Zaman S; Ances BM; Mapstone M; Head E; Lai F; Rosas HD; Klunk W; Christian B;
J Alzheimers Dis; 2023; 95(1):213-225. PubMed ID: 37482997
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of Alzheimer's disease in mothers of adults with Down's syndrome.
Schupf N; Kapell D; Lee JH; Ottman R; Mayeux R
Lancet; 1994 Aug; 344(8919):353-6. PubMed ID: 7914304
[TBL] [Abstract][Full Text] [Related]
9. [Clinical-therapeutic study of dementia in people with Down syndrome and the effectiveness of donepezil in this population].
Boada-Rovira M; Hernández-Ruiz I; Badenas-Homiar S; Buendía-Torras M; Tárraga-Mestre L
Rev Neurol; 2005 Aug 1-15; 41(3):129-36. PubMed ID: 16047294
[TBL] [Abstract][Full Text] [Related]
10. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study.
Prasher VP; Adams C; Holder R;
Int J Geriatr Psychiatry; 2003 Jun; 18(6):549-51. PubMed ID: 12789681
[No Abstract] [Full Text] [Related]
11. Telomere longitudinal shortening as a biomarker for dementia status of adults with Down syndrome.
Jenkins EC; Ye L; Krinsky-McHale SJ; Zigman WB; Schupf N; Silverman WP
Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):169-74. PubMed ID: 26593971
[TBL] [Abstract][Full Text] [Related]
12. Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.
Head E; Doran E; Nistor M; Hill M; Schmitt FA; Haier RJ; Lott IT
J Alzheimers Dis; 2011; 23(3):399-409. PubMed ID: 21116050
[TBL] [Abstract][Full Text] [Related]
13. A Multicentre Italian Validation Study in Aging Adults with Down Syndrome and Other Forms of Intellectual Disabilities: Dementia Screening Questionnaire for Individuals with Intellectual Disabilities.
Gomiero T; Bertelli M; Deb S; Weger E; Marangoni A; De Bastiani E; Mantesso U; De Vreese LP
Curr Alzheimer Res; 2017; 14(7):709-721. PubMed ID: 28124590
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Aging, Dementia, and Multimorbidity in Older Adults With Down Syndrome.
Bayen E; Possin KL; Chen Y; Cleret de Langavant L; Yaffe K
JAMA Neurol; 2018 Nov; 75(11):1399-1406. PubMed ID: 30032260
[TBL] [Abstract][Full Text] [Related]
15. Verbal intrusions precede memory decline in adults with Down syndrome.
Kittler P; Krinsky-McHale SJ; Devenny DA
J Intellect Disabil Res; 2006 Jan; 50(Pt 1):1-10. PubMed ID: 16316425
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal telomere shortening and early Alzheimer's disease progression in adults with down syndrome.
Jenkins EC; Marchi EJ; Velinov MT; Ye L; Krinsky-McHale SJ; Zigman WB; Schupf N; Silverman WP
Am J Med Genet B Neuropsychiatr Genet; 2017 Dec; 174(8):772-778. PubMed ID: 28856789
[TBL] [Abstract][Full Text] [Related]
17. Reduced short latency afferent inhibition in patients with Down syndrome and Alzheimer-type dementia.
Nardone R; Marth R; Ausserer H; Bratti A; Tezzon F
Clin Neurophysiol; 2006 Oct; 117(10):2204-10. PubMed ID: 16931146
[TBL] [Abstract][Full Text] [Related]
18. Increased "absence" of telomeres may indicate Alzheimer's disease/dementia status in older individuals with Down syndrome.
Jenkins EC; Ye L; Gu H; Ni SA; Duncan CJ; Velinov M; Pang D; Krinsky-McHale SJ; Zigman WB; Schupf N; Silverman WP
Neurosci Lett; 2008 Aug; 440(3):340-3. PubMed ID: 18571319
[TBL] [Abstract][Full Text] [Related]
19. Down syndrome.
Rafii MS; Kleschevnikov AM; Sawa M; Mobley WC
Handb Clin Neurol; 2019; 167():321-336. PubMed ID: 31753140
[TBL] [Abstract][Full Text] [Related]
20. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
